Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sofinnova Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
2,015,644Website Global Rank
8,743Website Monthly Traffic
Twitter Followers
Description
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2008 | mydeco | Series A | 14.5M |
| 6/2007 | PregLem | Series A | 26M |
| 3/2016 | TISSIUM | Series A | 25.5M |
| 2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
| 6/2019 | AFYX Therapeutics | Debt Financing | 13M |
| 7/2010 | Mainstay Medical | Series A | 6.1M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 4/2020 | Epsilen Bio | Seed Round | - |
| 11/2016 | Corwave | Series B | 17.1M |
| 7/2007 | Diatos | Series D | 12.8M |
| 11/2021 | Home Biosciences | Seed | 15M |
| 12/2007 | PregLem | Series B | 32.2M |
| 5/2020 | PinCell s.r.l. | Seed Round | 1.6M |
| 4/2022 | Prometheus Materials | Series A | 8M |
| 8/2021 | TISSIUM | Series C | 59.1M |
| 3/2010 | Omthera Pharmaceuticals | Series A | 6.5M |
| 4/2020 | EnginZyme | Series A | 6.9M |
| 7/2019 | Abivax | Post-IPO Equity | 13.5M |
| 1/2016 | ENYO Pharma | Series A | 23.9M |
| 4/2013 | MedDay | Series A | 10.5M |
| 10/2002 | Cobion | Venture Round | 5.9M |
| 8/2006 | Ablynx | Series C | 50M |
| 8/2000 | BioSpace | Series B | 10M |
| 12/2007 | Ascendis Pharma | Series A | 25.7M |
| 4/2022 | LimFlow SA | Series D | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 12/2019 | GenSight Biologics | Post-IPO Debt | 16.6M |
| 9/2010 | Bee Ware | Series B | 5.6M |
| 5/2005 | Bee Ware | Series A | 3.8M |
| 3/2008 | Filao | Venture Round | 0 |
| 3/2005 | Sequoia Pharmaceuticals | Series B | 22M |
| 4/2014 | ProQR Therapeutics | Series A | 57.9M |
| 3/2005 | Filao | Venture Round | 4.6M |
| 1/2006 | Blyk | Series A | 35.4M |
| 3/2016 | CelluComp | Venture Round | 5.3M |
| 7/2020 | Enthera | Series A | 0 |
| 11/2021 | Synthace | Series C | 35M |
| 3/2018 | SafeHeal | Series A | 7.4M |
| 5/2004 | Addex Therapeutics | Series B | 0 |
| 1/2007 | Stentys | Seed Round | - |
| 9/2013 | Synthace | Seed Round | 2.1M |
| 10/2022 | Mablink Bioscience | Series A | 30.1M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 1/2010 | BioAmber | Series A | 0 |
| 7/2021 | protera | Series A | 0 |
| 3/2009 | Neosens | Series B | 5.3M |
| 2/2008 | Neosens | Venture Round | 3.7M |
| 11/2013 | Pixium Vision | Series A | 20.3M |
| 3/2007 | MXP4 | Series A | 6.5M |
| 1/2004 | Infra Worlds | Series A | 1.7M |
| 5/2009 | MXP4 | Series B | 2.7M |
| 7/2009 | EOS (Ethical Oncology Science) | Series A | 17M |
| 2/2019 | GenSight Biologics | Post-IPO Equity | 9.1M |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 5/2023 | BrightHeart | Seed Round | 2.1M |
| 4/2020 | RefleXion Medical | Series D | 0 |
| 1/2008 | CrestaTech | Series A | 5M |
| 1/2005 | CrestaTech | Seed Round | 1.5M |
| 11/2011 | NuCana BioMed | Series A | 10.5M |
| 1/2013 | ProQR Therapeutics | Seed Round | - |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 3/2018 | Micropep Technologies | Series A | 5M |
| 3/2008 | Laszlo Systems | Series C | 14.6M |
| 4/2016 | MedDay | Series B | 0 |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
| 1/2009 | DBV Technologies | Series B | 7.8M |
| 1/2006 | DBV Technologies | Venture Round | 15.1M |
| 2/2003 | Avaki | Series A | 4.2M |
| 4/2006 | Endoart | Series C | 0 |
| 12/2021 | DMC Biotechnologies | Series B | 0 |
| 12/2019 | DMC Biotechnologies | Series A | 0 |
| 12/2022 | EnginZyme | Series B | 22.3M |
| 2/2017 | Zyl | Venture Round | - |
| 5/2022 | GFBiochemicals | Series A | 0 |
| 7/2019 | AblaCare | Series A | 11.2M |
| 12/2013 | Crescendo Biologics | Series A | 28.5M |
| 12/2018 | Shockwave Medical | Series D | 0 |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 3/2017 | Biotalys | Series B | 0 |
| 1/2002 | Innate Pharma | Series B | 17.8M |
| 4/2004 | Ablynx | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 7/2007 | Inside Secure | Series B | 0 |
| 3/2000 | Innate Pharma | Series A | 4.4M |
| 3/2023 | Noema Pharma | Series B | 0 |
| 11/2003 | Esmertec AG | Series C | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 12/2013 | Green Biologics | Series B | 0 |
| 7/2006 | Accent | Venture Round | 13.3M |
| 1/2009 | Revolt Technology | Series B | 13.1M |
| 10/2006 | Domain Therapeutics | Series C | 10.4M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 6/2005 | Revolt Technology | Series A | 8.5M |
| 5/2015 | Twenga | Series A | 11M |
| 4/2008 | Qosmos | Series C | 10.8M |
| 6/2021 | Borea Therapeutics | Seed Round | - |
| 10/1998 | BoostWorks | Series A | 3M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 2/2002 | Tak Imaging | Series B | 9.5M |
| 1/2004 | Intransa | Series C | 8M |
| 1/2005 | VoluBill | Series C | 0 |
| 11/2021 | GlycoEra | Series A | 0 |
| 10/2004 | Sensitive Object | Series A | 2.5M |
| 5/2010 | Crocus Technology | Series C | 0 |
| 9/2019 | Inotrem | Series B | 43.1M |
| 7/2007 | GlycoVaxyn | Series A | 9.5M |
| 4/2018 | LimFlow SA | Series C | 33.4M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 8/2022 | F2G | Private Equity Round | 0 |
| 7/2005 | Filao | Venture Round | 0 |
| 9/2007 | Purple Labs | Series A | 12.7M |
| 6/2019 | Comet Therapeutics | Series A | 28.5M |
| 4/2002 | Esmertec AG | Venture Round | 8.8M |
| 1/2019 | HighLife | Series B | 36M |
| 7/2021 | protera | Series A | 0 |
| 11/2002 | PhyFlex Networks | Series B | 0 |
| 4/2013 | Aledia | Series A | 12.8M |
| 7/2021 | Micropep Technologies | Series A | 10.1M |
| 6/2022 | Micropep Technologies | Series A | 0 |
| 2/2002 | Domain Therapeutics | Series A | 2.6M |
| 4/2020 | Pi-Cardia | Venture Round | 27M |
| 1/2007 | Movetis | Series A | 63.8M |
| 6/2010 | QuesCom | Venture Round | 0 |
| 1/2003 | Intransa | Series B | 6M |
| 7/2019 | Biotalys | Series C | 0 |
| 10/2010 | ASSIA | Series D | 20.8M |
| 7/2020 | Pixium Vision | Post-IPO Equity | 8.3M |
| 7/2002 | Addex Therapeutics | Series A | 9.9M |
| 9/2017 | Synthace | Series A | 9.9M |
| 10/2018 | Sitryx Therapeutics | Series A | 30M |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
| 4/2005 | Tak Imaging | Series C | 10M |
| 9/2002 | Ablynx | Series A | 4.9M |
| 3/2004 | UPEK | Series A | 20M |
| 11/2005 | Fovea Pharmaceuticals | Series A | 24.2M |
| 6/2020 | Protera | Series A | 5.6M |
| 1/2004 | Tak Imaging | Series C | 16.3M |
| 7/1999 | BoostWorks | Series B | 7M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 12/2007 | Streamezzo | Series C | 22M |
| 3/2008 | Mobile Digital Media | Venture Round | 0 |
| 7/2019 | Comet Biorefining | Venture Round | - |
| 8/2004 | Intransa | Series D | 24M |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 2/2013 | MetGen | Venture Round | 2.9M |
| 1/2015 | Green Biologics | Equity | 42M |
| 1/2005 | Biolipox | Series C | 41M |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 5/2010 | Noxxon Pharma | Series D | 40.7M |
| 10/2009 | Crescendo Biologics | Seed Round | 0 |
| 2/2002 | Intransa | Venture Round | 10M |
| 2/2015 | Synthace | Venture Round | 3.4M |
| 11/2006 | CoreValve | Venture Round | 20M |
| 3/2014 | Inotrem | Series A | 25.1M |
| 7/2006 | GlycoVaxyn | Seed Round | - |
| 5/2007 | Noxxon Pharma | Series C | 50.2M |
| 5/2004 | Domain Therapeutics | Series B | 19.1M |
| 1/2018 | Aledia | Series C | 0 |
| 5/2014 | Avantium | Series G | 0 |
| 11/2018 | InCarda Therapeutics | Series B | 42M |
| 4/2018 | Erydel | Series B | 32.4M |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 9/2020 | POLYNEURON | Series A | 15.4M |
| 2/2012 | BioAmber | Series C | 0 |
| 4/2014 | RefleXion Medical | Series A | 11.6M |
| 11/2014 | myTomorrows | Venture Round | 5.6M |
| 10/2017 | HighLife | Series A | 14.3M |
| 10/2011 | Creabilis | Series B | 20M |
| 7/2018 | HotSpot Therapeutics | Series A | 45M |
| 5/2018 | Biosyntia | Series A | 4.7M |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 3/2009 | GlycoVaxyn | Series B | 21.4M |
| 11/2019 | TISSIUM | Series B | 43.2M |
| 6/2015 | Aledia | Series B | 0 |
| 4/2006 | Varioptic | Series C | 0 |
| 7/2019 | Microphyt | Venture Round | 31.9M |
| 6/2018 | Castle Biosciences | Venture Round | 0 |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 4/2015 | ReCor Medical | Series D | 15M |
| 1/2008 | TAK imaging | Series C | 16.2M |
| 6/2009 | blueKiwi software | Series B | 0 |
| 9/2002 | EnvoyWorldWide | Series C | 4.5M |
| 6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
| 2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
| 12/2021 | EndoRon Medical | Seed Round | 5M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 1/2007 | blueKiwi software | Series A | 5.3M |
| 1/2003 | Biolipox | Series B | 21M |
| 3/2008 | Stentys | Series A | 18M |
| 2/2019 | AFYREN | Venture Round | 23.8M |
| 2/2021 | Mainstay Medical | Private Equity Round | 0 |
| 6/2018 | NodThera | Series A | 40M |
| 10/2021 | Leucid Bio | Series A | 15.9M |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 7/2022 | Biosyntia | Series B | 11.7M |
| 10/2003 | Cotherix | Series C | 55M |
| 1/2011 | DBV Technologies | Series C | 25.5M |
| 5/2019 | CinCor Pharma | Series A | 50M |
| 4/2014 | NuCana | Series B | 0 |
| 3/2004 | Varioptic | Series B | 12.2M |
| 3/2007 | CoreValve | Series C | 33M |
| 9/2004 | Innate Pharma | Series C | 0 |
| 5/2009 | Streamezzo | Series D | 5.5M |
| 4/2016 | RefleXion Medical | Series B | 52M |
| 4/2018 | RefleXion Medical | Series C | 100M |
| 2/2016 | Corvidia | Series A | 26M |
| 4/2018 | EnobraQ | Seed Round | 3.6M |
| 10/2016 | MD Start | Venture Round | 0 |
| 1/2007 | Sequoia Pharmaceuticals | Series C | 35M |
| 4/2006 | Streamezzo | Series B | 0 |
| 11/2016 | Shockwave Medical | Series C | 45M |
| 7/2021 | Comet Biorefining | Series C | 0 |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 3/2017 | Comet Biorefining | Venture Round | - |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 6/2013 | MetGen | Series A | - |
| 6/2021 | Alia Therapeutics | Seed Round | - |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 8/2005 | Abionyx Pharma | Series A | 30.5M |
| 5/2015 | Shockwave Medical | Series B | 40M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 12/2020 | Noema Pharma | Series A | 60M |
| 1/2008 | Inside Secure | Series C | 0 |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 4/2005 | Laszlo Systems | Series B | 6.3M |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 9/2007 | VoluBill | Series D | 0 |
| 1/2017 | myTomorrows | Venture Round | 10.6M |
| 6/2020 | NodThera | Series B | 55M |
| 3/2011 | Omthera Pharmaceuticals | Series B | 33.9M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 3/2017 | Breath Therapeutics | Series A | 45.9M |
| 4/2018 | Corvidia | Series B | 60M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 2/2010 | Odoo | Series A | 4.1M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 1/2021 | Corwave | Series C | 43.2M |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 4/2020 | Pyrowave | Series B | - |
| 7/2018 | Enthera | Seed Round | 4.7M |
| 9/2006 | Qosmos | Series B | 4.1M |
| 11/2013 | CelluComp | Seed Round | 3.9M |
| 6/2022 | Moon Surgical | Series A | 31.3M |
| 1/2014 | Shockwave Medical | Series A | 12.5M |
| 2/2022 | Elicit Plant | Series A | 18.3M |
| 6/2021 | AAVantgarde Bio | Seed Round | - |
| 4/2013 | Auris Medical | Series C | 51M |
| 1/2003 | Varioptic | Series A | 2.1M |
| 3/2017 | HotSpot Therapeutics | Seed Round | - |
| 2/2015 | Comet Biorefining | Venture Round | - |
| 1/2002 | EnvoyWorldWide | Series B | 8M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 10/2021 | Sphere Fluidics | Venture Round | 41.4M |
| 2/2013 | Entourage Medical Technologies | Venture Round | 3.3M |
| 11/2020 | Myricx Pharma | Seed Round | 5.9M |
| 3/2019 | POLYNEURON | Series A | 22.6M |
| 12/2009 | Sensitive Object | Series B | 6M |
| 9/2019 | Inventiva Pharma | Post-IPO Equity | 681.2k |
| 4/2020 | Genespire | Series A | 17.4M |
| 11/2011 | NuCana | Series A | 0 |
| 4/2005 | TAK imaging | Series C | 10M |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 6/2008 | Creabilis | Series A | 31.4M |
| 11/2022 | Microphyt | Series B | 0 |
| 10/2006 | Wyplay | Series A | 5.1M |
| 9/2006 | Oxxius | Series B | 10M |
| 6/2005 | Endotis | Series A | 4.9M |
| 5/2014 | Odoo | Series B | 10M |
| 5/2005 | Sefas Innovation | Venture Round | 3.8M |
| 9/2016 | Delinia | Series A | 35M |
| 1/2022 | SafeHeal | Venture Round | 0 |
| 9/2004 | Oxxius | Series A | 2.9M |
| 5/2023 | BrightHeart | Seed Round | 0 |
| 5/2023 | TISSIUM | Series D | 0 |
| 5/2023 | Moon Surgical | Series B | 0 |
| 5/2023 | Werewool | Seed Round | 0 |
| 4/2023 | Alia Therapeutics | Seed Round | 0 |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 3/2023 | deepc | Series A | 0 |
| 3/2023 | Kiro | Series A | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
